Taken together, these results reveal the importance of an intact G1/S transition for palbociclib response and provide a rationale for utilizing Rb in combination with LMWE as biomarkers of response to the combination of CDK4/6, aromatase and autophagy inhibitors in ER+ breast cancer. The gene discussed is CYP19A1; the disease is breast carcinoma.